Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
J Neurol. 2024 Feb;271(2):782-793. doi: 10.1007/s00415-023-12006-4. Epub 2023 Oct 6.
Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.
To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.
Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik®.
In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.
PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.
进行性核上性麻痹（PSP）通常发生在老年人中。目前，人们对这些患者的合并症和共同用药知之甚少。
根据已知的不同表型，探索 PSP 患者的合并症和共同用药模式，并与无神经退行性疾病的患者进行比较。
从三个德国多中心观察性研究（DescribePSP、ProPSP 和 DANCER）中收集 PSP 和无神经退行性疾病（non-ND）患者的横断面数据。根据世界卫生组织 ICD-10 分类分析合并症的患病率，根据世界卫生组织 ATC 系统分析用药的患病率。使用 AiDKlinik® 评估潜在的药物相互作用。
本分析共纳入 335 例 PSP 和 275 例 non-ND 患者。在 ICD-10 的第一级，PSP 患者的循环和神经系统疾病患病率较高。在 ICD-10 的第二级，PSP 患者更容易出现脊椎病、糖尿病、其他营养缺乏症和多发性神经病。特别是，心血管和脑血管疾病的总患病率在 PSP 患者中较高。PSP 组使用的药物更多，导致更多的患者接受多药治疗。因此，PSP 患者发生药物相互作用的可能性更高，尤其是严重和中度相互作用。
PSP 患者存在特定的合并症特征，特别是糖尿病和心血管疾病。在治疗 PSP 患者时，应仔细考虑合并症和由此导致的多药治疗的负担。
